Evoke Pharma Net Income 2012-2024 | EVOK
Evoke Pharma net income from 2012 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Evoke Pharma Annual Net Income
(Millions of US $) |
| 2023 |
$-8 |
| 2022 |
$-8 |
| 2021 |
$-9 |
| 2020 |
$-13 |
| 2019 |
$-7 |
| 2018 |
$-8 |
| 2017 |
$-12 |
| 2016 |
$-11 |
| 2015 |
$-12 |
| 2014 |
$-13 |
| 2013 |
$-3 |
| 2012 |
$-2 |
| 2011 |
$-2 |
Evoke Pharma Quarterly Net Income
(Millions of US $) |
| 2024-06-30 |
$-1 |
| 2024-03-31 |
$-2 |
| 2023-12-31 |
$-2 |
| 2023-09-30 |
$-2 |
| 2023-06-30 |
$-2 |
| 2023-03-31 |
$-2 |
| 2022-12-31 |
$-2 |
| 2022-09-30 |
$-2 |
| 2022-06-30 |
$-2 |
| 2022-03-31 |
$-2 |
| 2021-12-31 |
$-2 |
| 2021-09-30 |
$-2 |
| 2021-06-30 |
$-2 |
| 2021-03-31 |
$-3 |
| 2020-12-31 |
$-2 |
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-2 |
| 2019-12-31 |
$-1 |
| 2019-09-30 |
$-2 |
| 2019-06-30 |
$-2 |
| 2019-03-31 |
$-2 |
| 2018-12-31 |
$-2 |
| 2018-09-30 |
$-2 |
| 2018-06-30 |
$-2 |
| 2018-03-31 |
$-2 |
| 2017-12-31 |
$-0 |
| 2017-09-30 |
$-5 |
| 2017-06-30 |
$-2 |
| 2017-03-31 |
$-5 |
| 2016-12-31 |
$-2 |
| 2016-09-30 |
$-3 |
| 2016-06-30 |
$-3 |
| 2016-03-31 |
$-3 |
| 2015-12-31 |
$-3 |
| 2015-09-30 |
$-3 |
| 2015-06-30 |
$-3 |
| 2015-03-31 |
$-4 |
| 2014-12-31 |
$-3 |
| 2014-09-30 |
$-4 |
| 2014-06-30 |
$-4 |
| 2014-03-31 |
$-3 |
| 2013-12-31 |
$-2 |
| 2013-09-30 |
$-0 |
| 2013-06-30 |
$-0 |
| 2013-03-31 |
$-0 |
| 2012-12-31 |
|
| 2012-09-30 |
$-0 |
| 2012-06-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.005B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
